GOSS
Price
$0.17
Change
+$0.01 (+6.25%)
Updated
Jul 2, 04:59 PM (EDT)
Capitalization
84.67M
37 days until earnings call
Intraday BUY SELL Signals
ZVRA
Price
$13.98
Change
+$0.17 (+1.23%)
Updated
Jul 2, 04:59 PM (EDT)
Capitalization
826.43M
44 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

GOSS vs ZVRA

GOSS vs ZVRA Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
GOSS vs. ZVRA commentary
Jul 05, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GOSS is a Hold and ZVRA is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 05, 2026
Stock price -- (GOSS: $0.16 vs. ZVRA: $13.52)
Brand notoriety: GOSS and ZVRA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GOSS: 237% vs. ZVRA: 136%
Market capitalization -- GOSS: $84.67M vs. ZVRA: $826.43M
GOSS [@Biotechnology] is valued at $84.67M. ZVRA’s [@Biotechnology] market capitalization is $826.43M. The market cap for tickers in the [@Biotechnology] industry ranges from $134.02B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GOSS’s FA Score shows that 0 FA rating(s) are green whileZVRA’s FA Score has 1 green FA rating(s).

  • GOSS’s FA Score: 0 green, 5 red.
  • ZVRA’s FA Score: 1 green, 4 red.
According to our system of comparison, ZVRA is a better buy in the long-term than GOSS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GOSS’s TA Score shows that 4 TA indicator(s) are bullish while ZVRA’s TA Score has 3 bullish TA indicator(s).

  • GOSS’s TA Score: 4 bullish, 3 bearish.
  • ZVRA’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, GOSS is a better buy in the short-term than ZVRA.

Price Growth

GOSS (@Biotechnology) experienced а -4.96% price change this week, while ZVRA (@Biotechnology) price change was +2.19% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.30%. For the same industry, the average monthly price growth was +5.93%, and the average quarterly price growth was +1921.84%.

Reported Earning Dates

GOSS is expected to report earnings on Aug 11, 2026.

ZVRA is expected to report earnings on Aug 18, 2026.

Industries' Descriptions

@Biotechnology (+2.30% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ZVRA($826M) has a higher market cap than GOSS($84.7M). ZVRA YTD gains are higher at: 50.893 vs. GOSS (-94.935). ZVRA has higher annual earnings (EBITDA): 144M vs. GOSS (-168.59M). ZVRA has more cash in the bank: 201M vs. GOSS (99.2M). ZVRA has less debt than GOSS: ZVRA (1.15M) vs GOSS (203M). ZVRA has higher revenues than GOSS: ZVRA (122M) vs GOSS (55.5M).
GOSSZVRAGOSS / ZVRA
Capitalization84.7M826M10%
EBITDA-168.59M144M-117%
Gain YTD-94.93550.893-187%
P/E RatioN/A6.29-
Revenue55.5M122M45%
Total Cash99.2M201M49%
Total Debt203M1.15M17,698%
FUNDAMENTALS RATINGS
GOSS vs ZVRA: Fundamental Ratings
GOSS
ZVRA
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
49
Fair valued
89
Overvalued
PROFIT vs RISK RATING
1..100
10086
SMR RATING
1..100
10012
PRICE GROWTH RATING
1..100
9537
P/E GROWTH RATING
1..100
10097
SEASONALITY SCORE
1..100
38n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GOSS's Valuation (49) in the Pharmaceuticals Major industry is somewhat better than the same rating for ZVRA (89) in the null industry. This means that GOSS’s stock grew somewhat faster than ZVRA’s over the last 12 months.

ZVRA's Profit vs Risk Rating (86) in the null industry is in the same range as GOSS (100) in the Pharmaceuticals Major industry. This means that ZVRA’s stock grew similarly to GOSS’s over the last 12 months.

ZVRA's SMR Rating (12) in the null industry is significantly better than the same rating for GOSS (100) in the Pharmaceuticals Major industry. This means that ZVRA’s stock grew significantly faster than GOSS’s over the last 12 months.

ZVRA's Price Growth Rating (37) in the null industry is somewhat better than the same rating for GOSS (95) in the Pharmaceuticals Major industry. This means that ZVRA’s stock grew somewhat faster than GOSS’s over the last 12 months.

ZVRA's P/E Growth Rating (97) in the null industry is in the same range as GOSS (100) in the Pharmaceuticals Major industry. This means that ZVRA’s stock grew similarly to GOSS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GOSSZVRA
RSI
ODDS (%)
Bullish Trend 4 days ago
90%
Bearish Trend 4 days ago
85%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
80%
Bearish Trend 4 days ago
79%
Momentum
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
76%
MACD
ODDS (%)
Bullish Trend 5 days ago
82%
Bullish Trend 4 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
87%
Bullish Trend 4 days ago
78%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
79%
Advances
ODDS (%)
Bullish Trend 20 days ago
84%
Bullish Trend 10 days ago
80%
Declines
ODDS (%)
Bearish Trend 10 days ago
87%
Bearish Trend 21 days ago
74%
BollingerBands
ODDS (%)
N/A
Bearish Trend 4 days ago
79%
Aroon
ODDS (%)
Bearish Trend 4 days ago
90%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
GOSS
Daily Signal:
Gain/Loss:
ZVRA
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MSJSX22.590.02
+0.09%
Morgan Stanley Global Endurance R6
AIECX18.250.01
+0.05%
Invesco EQV International Equity C
TRPWX21.03N/A
N/A
Nuveen Quant Mid Cap Growth R6
TRPGX16.02N/A
N/A
Nuveen Core Equity Premier
BLYYX40.00-0.45
-1.11%
American Beacon Man Lg Cp Growth Y

GOSS and

Correlation & Price change

A.I.dvisor indicates that over the last year, GOSS has been loosely correlated with LITS. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if GOSS jumps, then LITS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GOSS
1D Price
Change %
GOSS100%
N/A
LITS - GOSS
46%
Loosely correlated
N/A
APVO - GOSS
41%
Loosely correlated
N/A
NUVL - GOSS
39%
Loosely correlated
N/A
IDYA - GOSS
38%
Loosely correlated
N/A
XNCR - GOSS
38%
Loosely correlated
N/A
More